DiscussierRegeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ: REGN) is a leading biotechnology company known for its innovative drug discovery platform and blockbuster portfolio anchored by Eylea for retinal diseases, Dupixent for inflammatory conditions, and Libtayo for certain cancers, with Dupixent alone generating over $10 billion in annual global sales. The company's proprietary VelociSuite technology platform enables rapid and efficient drug development, consistently producing a pipeline that ranks among the most...